1.Name and nature of the underlying security (if preferred shares, the terms
and conditions of issuance shall also be indicated, e.g., dividend yield):
Partnership interests of「CDIB Capital Healthcare Ventures III Limited
Partnership」(tentatively name, hereinafter referred to as “Healthcare
Fund III”)
2.Date of occurrence of the event:2026/08/31
3.No., unit price, and monetary amount of the transaction:
No., unit price: Not applicable due to partnership interests investment,
total monetary amount of the transaction: CVC and CCM will jointly commit
up to 31% (inclusive) of the fund size or NT$ 930 million (inclusive)
(whichever is lower), with CVC contributing up to 30% (inclusive) and CCM
up to 1% (inclusive).
4.Counterparty to the trade and its relationship to the company (if the
trading counterparty is a natural person and not a related party of the
company, its name is not required to be disclosed):
Counterparty：「Healthcare Fund III」proposed to be established
Its relationship to the Company：Related party disclosed in financial
statements upon its establishment.
5.Where the counterparty to the trade is a related party, an announcement
shall also be made of the reason for choosing the related party as trading
counterparty and the identity of the previous owner, including its
relationship with the company and the trading counterparty, the price of the
ownership transfer, and date of transfer:
A new fund to be raised by CDIB Group; No previous transfer.
6.Where the owner of the underlying securities within the past five years
has been a related party of the company, an announcement shall also include
the dates and prices of acquisition and disposal by the related party and
its relationship with the company at the time: N/A
7.Matters related to the creditor’s rights currently being disposed of
(including type of collateral of the disposed creditor’s rights; if the
creditor’s rights are creditor’s rights over a related party, the name of
the related party and the book amount of such creditor’s rights currently
being disposed of must also be announced): N/A
8.Profit (or loss) from the disposal (not applicable in cases of acquisition
of securities) (where originally deferred, the status or recognition shall
be stated and explained): N/A
9.Terms of delivery or payment (including payment period and monetary
amount), restrictive covenants in the contract, and other important
stipulations: Per the fund-related agreements.
10.The manner in which the current transaction was decided, the reference
basis for the decision on price, and the decision-making unit:
Per fund-related agreements.
The decision-making department：The Board.
11.Net worth per share of company of the underlying securities acquired or
disposed of: N/A
12.The discrepancy between the reference price of private placement company
and the transaction amount per share is 20 percent or more: N/A
13.Current cumulative no., amount, and shareholding ratio of the securities
being traded (including the current transaction) as of the date of
occurrence and status of any restriction of rights (e.g.,pledges):
(1)Current cumulative volume: N/A due to partnership interests investment.
(2)Amount and shareholding ratio of the securities being traded: CVC and
CCM will jointly commit up to 31% (inclusive) of the fund size or
NT$ 930 million (inclusive) (whichever is lower), with CVC
contributing up to 30% (inclusive) and CCM up to 1% (inclusive).
(3)Status of any restriction of rights: None.
14.Privately placed securities (including the current transaction) as a
percentage of total assets of the company and shareholder’s equity of the
parent company on the latest financial statements, and the operating capital
on the latest financial statements as of the date of occurrence:
(1)to the total assets: 0.03%(CCM)、0.62%(CVC)
(2)to the shareholder's equity attributable to owners of the parent:
0.03%(CCM)、0.74%(CVC)
(3)The operating capital: N/A.
15.Broker and broker's fee: N/A
16.Concrete purpose or use of the acquisition or disposition:
For the needs of investment business development
17.Whether the directors expressed any objection to the present transaction:No
18.Whether the trading counterparty is a related party: Yes
19.Date of approval by board of directors:2026/08/31
20.Recognition date by supervisors or approval date by audit committee:
N/A, the procedure under Article 45 of the Financial Holding Company Act
shall apply.
21.Whether the CPA issued an opinion on the unreasonableness of the current
transaction: N/A
22.Name of the CPA firm: N/A
23.Name of the CPA: N/A
24.License no.of the CPA: N/A
25.Any other matters that need to be specified:
(1)“CCM” refers to Capital Management Corporation, and “CVC” refers
to CDIB Venture Capital Corporation.
(2) The investment terms for Healthcare Fund III, previously announced on
March 7, 2025, have been revised following a review by the boards of
CVC and CCM. The aggregate investment is capped at the lower of 31%
of the fund size or NT$ 0.93 billion. The announcement has been
updated accordingly.